First Financial Equity Corporation’s Vertex Pharmaceuticals VRTX Stock Holding History

First Financial Equity Corporation’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$262K	Buy	+2,436	New	+$214K	0.04%	344

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

First Financial Equity Corporation's VRTX Position: Q1 2017 in Review

First Financial Equity Corporation opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2017: 2,436 shares worth $262K. The stake represents 0.04% of the portfolio and ranks #344 among its holdings.

522 funds tracked by Wall St. Rank hold VRTX as of Q1 2017.

First Financial Equity Corporation held 2,436 shares of Vertex Pharmaceuticals worth $262K as of Q1 2017.
Vertex Pharmaceuticals was a new First Financial Equity Corporation position in Q1 2017.
Vertex Pharmaceuticals made up 0.04% of First Financial Equity Corporation's portfolio in Q1 2017, its #344 holding.
522 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2017.

Based on First Financial Equity Corporation's 13F filing for Q1 2017, filed 16 May 2017.